相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Chemistry, Multidisciplinary
Yutian Zou et al.
Summary: This study utilizes single-cell RNA sequencing to construct a high-resolution map of the tumor ecosystem in liver and brain metastases of breast cancer. The results show remarkable reprogramming of immunosuppressive cells in the metastatic ecosystem, as well as the negligible expression of PD-1 and PD-L1/2 in CD8+ T cells and cancer/immune/stromal cells. The interactions between LAG3-LGALS3 and TIGIT-NECTIN2 are found to play dominant roles in immune escape.
Review
Biology
Shovan Dutta et al.
Summary: Tumor immune escape mechanisms are major obstacles to successful cancer treatment. Despite host immunity, cancer cells can avoid detection and resistance from immune cell responses. New targets and strategies are crucial for efficacious immune responses. This review discusses classical immune checkpoint targets and explores emerging immunotherapeutic targets.
Article
Oncology
Jiancheng Lv et al.
Summary: This study found that circFAM13B is downregulated in patients with bladder cancer (BCa) and is associated with lower tumor stage and better prognosis. circFAM13B promotes the function of CD8(+) T cells and inhibits glycolysis and acidic tumor microenvironment in BCa. By competitively binding to IGF2BP1 and PKM2 3'UTR, circFAM13B reduces the stability of PKM2 mRNA and inhibits glycolysis-induced acidic tumor microenvironment. This study suggests that circFAM13B can serve as a biomarker for guiding immune therapy in BCa patients.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Maria Tagliamonte et al.
Summary: The development of cancer immunotherapeutic strategies relies on the identification and validation of optimal target tumor antigens, which should be tumor-specific as well as able to elicit a swift and potent anti-tumor immune response. Most strategies are based on tumor associated antigens (TAAs), but these may be affected by immunological tolerance or elicit autoimmune responses. Therefore, non-self-antigens derived from microorganisms (MoAs) may be beneficial in overcoming these limitations.
Article
Oncology
Veronika Lutz et al.
Summary: Signaling through IL18R induces exhaustion of CD8(+) T cells, characterized by expression of coinhibitory receptors and loss of effector function. This exhaustion is mediated by an NLRP3-expressing tumor microenvironment that releases IL18. These findings suggest that NLRP3-mediated IL18R signaling could be a potential target for immunotherapy in pancreatic carcinoma.
CANCER IMMUNOLOGY RESEARCH
(2023)
Review
Oncology
Anshika Goenka et al.
Summary: Tumor development and metastasis are influenced by the complex interactions between cancer cells and their microenvironment, which includes stromal cells and extracellular matrix components. Understanding the signaling pathways involved in these interactions is crucial for developing effective intervention strategies. This review provides a comprehensive analysis of the diverse signaling pathways in the tumor microenvironment, highlighting the latest preclinical and clinical studies and their underlying biology.
CANCER COMMUNICATIONS
(2023)
Article
Oncology
Shaoquan Zheng et al.
Summary: This study systematically assessed the expression of fibroblasts in cancer patients and investigated the role of biglycan (BGN) in immunotherapy response. The study found that CAFs were closely correlated with immune components and that BGN, a specific secreting factor of CAFs, served as an unfavourable indicator for overall survival and immunotherapy response.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Rebecca L. Siegel et al.
Summary: The American Cancer Society predicts that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. While incidence trends for most cancers are favorable, prostate cancer saw a significant increase of 3% annually from 2014 to 2019. However, the overall cancer death rate continues to decline due to advances in treatment, with a 33% reduction since 1991.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Immunology
Gulce Sari et al.
Summary: CD8 T cells recognize cancers through antigenic peptides presented on a tumor's surface MHC-I molecules. Many cancers, by inactivating MHC-I antigen presentation, evade control by CD8 T cells. This review discusses recent findings on the various mechanisms that cancers employ to impair antigen presentation, the consequences of these changes, and the potential for reversing these defects in some cases.
CURRENT OPINION IN IMMUNOLOGY
(2023)
Review
Immunology
Xiaohu Zheng et al.
Summary: Cytokines play a critical role in immune regulation, but their clinical application is often limited by toxicity and lack of efficacy. Protein engineering and synthetic immunology provide new approaches to modify cytokine signaling and design engineered cytokines that selectively target specific cells.
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Review
Oncology
Sheng-Nan Jia et al.
Summary: Colon cancer is a common and highly fatal human cancer. Chemokines, particularly CCL20 and its receptor CCR6, play important roles in the progression of colon cancer. The interaction between CCL20-CCR6 and multiple signaling pathways has a profound effect on colon cancer hepatic metastasis. The elevated levels of CCL20 in colon tumors and metastatic patients indicate the potential of chemokines as diagnostic and prognostic biomarkers for colon cancer.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Loretah Chibaya et al.
Summary: Cancer therapies not only affect tumor cells, but also the tumor-immune microenvironment. Induction of cellular senescence can lead to durable tumor cell arrest and remodeling of the tumor-immune microenvironment through the production of SASP. Depending on the therapy, the SASP can either promote anti-tumor immunity or chronic inflammation, affecting the success of the treatment.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Caroline Plazy et al.
Summary: This review examines the reintroduction of immune checkpoint inhibitors (ICIs) after disease progression or immunerelated adverse events (irAEs) recovery. The heterogeneity of the results suggests that ICI rechallenge/resumption may be an effective strategy for selected patients. Factors such as good Eastern Cooperative Oncology Group Performance Status, longer duration of initial ICI treatment, and discontinuation of initial ICI for reasons other than disease progression have been associated with better outcomes. Furthermore, certain types of irAEs are more likely to relapse during retreatment.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Jindong Xie et al.
Summary: The FOXO transcription factors play important roles in various types of cancer and are closely related to tumor microenvironment, prognosis, and treatment sensitivity. The FOXOs score can be used as a potential biomarker to predict treatment efficacy in cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Xu Liu et al.
Summary: The promising results of immunotherapy in tumors have led to a change in the current treatment strategy for cancer. However, the limited effectiveness in a minority of patients is attributed to immune suppression in the tumor microenvironment. Recent evidence has shown that abnormal glucose metabolism plays a crucial role in tumor immune escape and can be targeted in combination with immunotherapy. By understanding the functions of glucose metabolism in tumor cells, immune cells, and the tumor microenvironment, strategies can be developed to improve tumor therapy by targeting glucose metabolism.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lihua Chen et al.
Summary: Lactate plays a crucial role in connecting immune evasion and metabolic reprogramming in cancer. Lactate metabolism promotes key processes in tumor development, and protein lactylation is essential for lactate's function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Yuchen Wang et al.
Summary: The discovery of immune checkpoint inhibitors is considered a significant breakthrough in tumor therapy, but severe side effects and ineffective treatment outcomes still exist. In addition to known molecules like PD-1/PD-L1 and CTLA-4, novel immune checkpoint molecules such as VISTA and CD39 are being widely investigated for potential clinical benefits.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Zhao-yan Liu et al.
Summary: In this study, the independent and joint associations of lifestyle and mental health with mortality in cancer survivors were evaluated. The results showed that adopting a healthy lifestyle and maintaining good mental health can improve the survival of cancer survivors. The combination of a higher healthy lifestyle score and better mental health was associated with the lowest mortality.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Medicine, General & Internal
Shen Pan et al.
Summary: This study analyzed the abnormal expression and prognostic value of RUNX genes in various cancers. The findings showed that RUNX genes are consistently overexpressed in esophageal, gastric, pancreatic, and pan-renal cancers. RUNX genes are significantly associated with survival in pan-renal cancer, brain lower-grade glioma, and uveal melanoma. Different mutations and posttranscriptional changes, including the RUNX1 D96 mutation in invasive breast carcinoma and methylation changes in the RUNX2 promoter in KIRC, may be associated with cancer development. The study also revealed the carcinogenicity, abnormal expression, and direct regulation of RUNX genes through the analysis of epigenetic regulator co-expression, miRNA networks, and target genes.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE
(2022)
Review
Oncology
Yavar Shiravand et al.
Summary: The discovery of immune checkpoint proteins has revolutionized cancer immunotherapy, leading to the successful utilization of targeted monoclonal antibodies in various cancer patients. However, not all patients respond favorably to these drugs, emphasizing the need for biomarkers to predict treatment responses.
Review
Biochemistry & Molecular Biology
William C. Hahn et al.
Summary: Characterization of cancer genomes has provided insight into somatically altered genes across tumors, but the function of most cancer alleles remains mysterious and does not impact therapy for most patients. Approaches to understand the function and circuitry of cancer genes provide complementary approaches to elucidate both oncogene and non-oncogene dependencies. Emerging work indicates that therapeutic targets engendered by non-oncogene dependencies are more diverse than recurrently mutated genes, providing new opportunities for clinical translation.
Article
Pathology
Yifang Wang et al.
Summary: In this study, it was found that in renal clear cell carcinoma (ccRCC), the mRNA level of CDH5 was significantly higher than in normal tissue, serving as a potential diagnostic biomarker. Additionally, the overexpression of mir-27a-3p was associated with the reduced expression of CDH5 and correlated with clinical stages in ccRCC patients.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Review
Oncology
Petros Grivas et al.
Summary: Avelumab as 1L maintenance therapy significantly prolonged OS in patients with locally advanced or metastatic UC that had not progressed with platinum-containing chemotherapy. The treatment showed efficacy benefits across various subgroups and is now included as a standard of care in treatment guidelines for advanced UC with level 1 evidence.
CANCER TREATMENT REVIEWS
(2021)
Review
Oncology
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY
(2020)
Review
Oncology
Xu Lei et al.
Review
Medicine, Research & Experimental
Keywan Mortezaee
Review
Oncology
Emmanuel N. Kontomanolis et al.
ANTICANCER RESEARCH
(2020)
Review
Oncology
Katie L. Owen et al.
Article
Pathology
Kyoko Higuchi et al.
JOURNAL OF CLINICAL PATHOLOGY
(2017)
Article
Medicine, General & Internal
Arjun V. Balar et al.
Article
Cell Biology
Loic Sauteur et al.
Article
Oncology
Xing-gang Mao et al.
Article
Oncology
Maryam Rezaei et al.
BREAST CANCER RESEARCH
(2012)
Article
Oncology
Myriam Labelle et al.
Review
Oncology
U Cavallaro et al.
EXPERIMENTAL CELL RESEARCH
(2006)
Article
Multidisciplinary Sciences
MJC Hendrix et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2001)
